Corbus Pharmaceuticals has announced updated clinical data from its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody-drug conjugate (ADC), targeting both head and neck squamous cell carcinoma (HNSCC) and cervical cancer. This data will be presented at the 2026 ASCO Annual Meeting, with a focus on clinical response durability and subgroup analyses for HNSCC patients. Previous presentations at the 2025 ESMO Congress highlighted promising efficacy and safety profiles, reinforcing the drug’s potential in these challenging malignancies.

The significance of CRB-701 lies in its design, featuring a site-specific, cleavable linker and a homogenous drug-antibody ratio of 2, utilizing MMAE as the payload. Nectin-4 is a clinically validated tumor-associated antigen, particularly in urothelial cancers, and the FDA has granted Fast Track designations for CRB-701 in both HNSCC and cervical cancer. Corbus anticipates initiating a registrational study for CRB-701 in second-line HNSCC by mid-2026 and is also set to report data on its combination with Keytruda® in first-line HNSCC patients later in 2026.

The takeaway from these developments is the potential shift in treatment paradigms for Nectin-4-expressing tumors. With the upcoming registrational studies and combination trials, CRB-701 could significantly impact drug development timelines for ADCs in oncology, particularly in settings where current therapies are limited. This positions Corbus as a key player in advancing targeted therapies, potentially improving outcomes for patients with recurrent or metastatic cancers.

Source: globenewswire.com